Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Investigators sought to determine if zanidatamab and chemotherapy, with or without tislelizumab, could extend PFS and OS in patients with untreated locally advanced or metastatic gastroesophageal ...

Gedatolisib's NDA for advanced breast cancer treatment has been accepted by the FDA, with a priority review and a PDUFA date set for July 17, 2026. The drug is intended for HR+/HER2–, PIK3CA wild-type ...

Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) significantly ...

Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell ...

Adding chemotherapy and bevacizumab to immunotherapy improves tumor control in a high-risk CRC subset, but this benefit comes ...

At the San Antonio Breast Cancer Symposium, researchers discussed how results from HER2CLIMB-05 may inform first-line ...